Welcome to Neuromics, a research project funded by the European Commission for five years.
In reality, so-called rare diseases are anything but rare. 6-8% of the European population – between 27 and 36 million people – are affected by one of the 5000-8000 distinct rare diseases. Neuromics studies 10 rare neurodegenerative and neuromuscular diseases...read more
Neuromics aims to revolutionize diagnostics and develop new treatments for ten major neuromuscular and neurodegenerative diseases.
It will do this by bringing together leading research groups in Europe, five highly innovative SMEs and overseas experts. Together, they will use the most sophisticated -omics technologies in order to:
increase the number of patients with a genetic diagnosis;
develop biomarkers for clinical application;
improve understanding of pathophysiology and identify drug targets;
identify disease modifiers;
develop targeted therapies;
translate findings to other, related disease groups.
Neurodegenerative (NDD) and neuromuscular (NMD) diseases are amongst the most frequent of rare diseases, affecting the life and mobility of more than 500,000 patients and families in Europe.
The focus of Neuromics is on 10 major disease categories. Some of these are at a promising stage of etiological and therapeutic research, whilst in others, diagnostic and therapeutic concepts are still preliminary. The conditions included are: